Baxter Return on Tangible Equity 2010-2024 | BAX
Current and historical return on tangible equity values for Baxter (BAX) over the last 10 years. Return on tangible equity can be defined as the amount of net income returned as a percentage of shareholders equity, after subtracting intangible assets, goodwill and preferred equity.
| Baxter Return On Tangible Equity Historical Data | |||
|---|---|---|---|
| Date | TTM Net Income | Tangible Equity | Return on Tangible Equity |
| 2024-12-31 | $-0.65B | $-3.47B | 17.43% |
| 2024-09-30 | $0.11B | $-3.29B | -2.95% |
| 2024-06-30 | $2.48B | $-4.03B | -62.49% |
| 2024-03-31 | $2.65B | $-4.10B | -55.56% |
| 2023-12-31 | $2.66B | $-3.24B | -47.14% |
| 2023-09-30 | $2.59B | $-4.47B | -38.91% |
| 2023-06-30 | $-2.85B | $-7.26B | 37.84% |
| 2023-03-31 | $-2.46B | $-7.57B | 31.64% |
| 2022-12-31 | $-2.43B | $-7.35B | 30.48% |
| 2022-09-30 | $-2.38B | $-7.99B | 28.73% |
| 2022-06-30 | $1.01B | $-8.20B | -19.03% |
| 2022-03-31 | $1.06B | $-8.39B | -44.14% |
| 2021-12-31 | $1.28B | $-8.51B | 230.52% |
| 2021-09-30 | $1.21B | $3.84B | 33.32% |
| 2021-06-30 | $1.12B | $3.48B | 30.77% |
| 2021-03-31 | $1.07B | $3.42B | 29.51% |
| 2020-12-31 | $1.10B | $3.84B | 31.33% |
| 2020-09-30 | $0.91B | $3.83B | 26.71% |
| 2020-06-30 | $0.92B | $3.39B | 27.96% |
| 2020-03-31 | $0.99B | $3.01B | 29.67% |
| 2019-12-31 | $1.00B | $3.41B | 29.34% |
| 2019-09-30 | $1.32B | $3.41B | 38.57% |
| 2019-06-30 | $1.47B | $3.53B | 39.13% |
| 2019-03-31 | $1.50B | $3.30B | 37.61% |
| 2018-12-31 | $1.55B | $3.45B | 36.12% |
| 2018-09-30 | $1.06B | $4.73B | 23.24% |
| 2018-06-30 | $0.80B | $4.46B | 17.19% |
| 2018-03-31 | $0.72B | $4.48B | 14.82% |
| 2017-12-31 | $0.60B | $4.64B | 12.12% |
| 2017-09-30 | $1.03B | $4.97B | 20.82% |
| 2017-06-30 | $0.91B | $5.31B | 18.53% |
| 2017-03-31 | $1.86B | $4.95B | 39.24% |
| 2016-12-31 | $4.97B | $4.57B | 105.02% |
| 2016-09-30 | $4.93B | $4.81B | 102.83% |
| 2016-06-30 | $4.80B | $4.60B | 106.16% |
| 2016-03-31 | $3.92B | $4.93B | 100.30% |
| 2015-12-31 | $0.97B | $4.83B | 31.69% |
| 2015-09-30 | $1.72B | $3.72B | 62.42% |
| 2015-06-30 | $2.18B | $2.15B | 91.87% |
| 2015-03-31 | $2.37B | $1.53B | 99.92% |
| 2014-12-31 | $2.50B | $3.61B | 98.27% |
| 2014-09-30 | $1.87B | $2.23B | 87.57% |
| 2014-06-30 | $1.95B | $2.13B | 102.41% |
| 2014-03-31 | $2.02B | $2.20B | 87.34% |
| 2013-12-31 | $2.01B | $1.99B | 77.39% |
| 2013-09-30 | $2.18B | $1.28B | 72.22% |
| 2013-06-30 | $2.22B | $3.76B | 60.73% |
| 2013-03-31 | $2.29B | $3.36B | 64.92% |
| 2012-12-31 | $2.33B | $3.66B | 65.04% |
| 2012-09-30 | $2.30B | $3.83B | 64.07% |
| 2012-06-30 | $2.29B | $3.26B | 61.58% |
| 2012-03-31 | $2.24B | $3.56B | 56.12% |
| 2011-12-31 | $2.22B | $3.69B | 52.85% |
| 2011-09-30 | $2.18B | $4.36B | 50.13% |
| 2011-06-30 | $2.13B | $4.37B | 49.36% |
| 2011-03-31 | $2.05B | $4.41B | 49.57% |
| 2010-12-31 | $1.42B | $4.28B | 34.94% |
| 2010-09-30 | $1.57B | $4.22B | 36.79% |
| 2010-06-30 | $1.57B | $3.66B | 35.42% |
| 2010-03-31 | $1.63B | $4.10B | 34.92% |
| 2009-12-31 | $2.21B | $5.08B | 47.32% |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical Products Manufacturing | $17.948B | $10.636B |
| Baxter International Inc. is a global medical technology company. The company consists of renal and hospital products, providing items such as kidney-dialysis equipment, infusion pumps, and intravenous (IV) solutions. Baxter has been reporting through six revenue segments. Renal Care, Medication Delivery, Pharmaceuticals, Clinical Nutrition, Advanced Surgery, Acute Therapies and Other. Baxter's Renal segment primarily consists of Peritoneal Dialysis (PD) and Hemodialysis (HD) therapies. The portfolio addresses the needs of patients with kidney failure or kidney disease, and their healthcare providers, with a comprehensive range of therapeutic options across home, in-center, and hospital settings for better individualized care. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Abbott Laboratories (ABT) | United States | $234.047B | 28.90 |
| Boston Scientific (BSX) | United States | $154.056B | 41.59 |
| Stryker (SYK) | United States | $148.022B | 31.82 |
| EssilorLuxottica (ESLOY) | France | $137.298B | 0.00 |
| Medtronic (MDT) | Ireland | $115.624B | 16.89 |
| Lonza Group Ag (LZAGY) | Switzerland | $46.792B | 0.00 |
| Haleon (HLN) | United Kingdom | $45.950B | 29.85 |
| GE HealthCare Technologies (GEHC) | United States | $41.418B | 20.17 |
| Agilent Technologies (A) | United States | $38.594B | 25.57 |
| ResMed (RMD) | United States | $33.728B | 25.98 |
| Terumo (TRUMY) | Japan | $25.984B | 36.95 |
| Koninklijke Philips (PHG) | Netherlands | $24.420B | 17.44 |
| Zimmer Biomet Holdings (ZBH) | United States | $21.098B | 13.25 |
| Insulet (PODD) | United States | $19.908B | 85.13 |
| Smith & Nephew SNATS (SNN) | United Kingdom | $11.490B | 0.00 |
| Sunny Optical Technology (SNPTF) | China | $11.331B | 0.00 |
| BellRing Brands (BRBR) | United States | $9.348B | 35.03 |
| Demant (WILYY) | Denmark | $8.092B | 0.00 |
| Bio-Rad Laboratories (BIO) | United States | $7.847B | 27.17 |
| Lantheus Holdings (LNTH) | United States | $5.489B | 12.75 |
| Prestige Consumer Healthcare (PBH) | United States | $4.215B | 20.11 |
| ICU Medical (ICUI) | United States | $3.924B | 37.35 |
| Envista Holdings (NVST) | United States | $3.683B | 29.30 |
| Perrigo (PRGO) | Ireland | $3.443B | 10.14 |
| Haemonetics (HAE) | United States | $3.312B | 15.58 |
| Shandong Weigao Medical Polymer (SHWGF) | China | $2.989B | 0.00 |
| GN Store Nord (GNNDY) | Denmark | $2.850B | 19.20 |
| QuidelOrtho (QDEL) | United States | $2.822B | 23.71 |
| LeMaitre Vascular (LMAT) | United States | $2.294B | 55.75 |
| Neogen (NEOG) | United States | $2.261B | 26.05 |
| AtriCure (ATRC) | United States | $1.916B | 0.00 |
| Green Thumb Industries (GTBIF) | United States | $1.494B | 26.06 |
| InMode (INMD) | Israel | $1.330B | 11.12 |
| BioLife Solutions (BLFS) | United States | $1.193B | 0.00 |
| AdaptHealth (AHCO) | United States | $1.150B | 8.22 |
| Maravai LifeSciences Holdings (MRVI) | United States | $1.013B | 0.00 |
| Curaleaf Holdings (CURLF) | Canada | $0.920B | 0.00 |
| CeriBell (CBLL) | United States | $0.911B | 0.00 |
| Phibro Animal Health (PAHC) | United States | $0.896B | 13.74 |
| Evolus (EOLS) | United States | $0.893B | 0.00 |
| Capricor Therapeutics (CAPR) | United States | $0.657B | 0.00 |
| Valneva SE (VALN) | France | $0.635B | 0.00 |
| VAREX IMAGING (VREX) | United States | $0.538B | 23.32 |
| Omeros (OMER) | United States | $0.503B | 0.00 |
| Surmodics (SRDX) | United States | $0.501B | 0.00 |
| Owens & Minor (OMI) | United States | $0.493B | 3.85 |
| SNDL (SNDL) | Canada | $0.439B | 0.00 |
| Cresco Labs (CRLBF) | United States | $0.432B | 0.00 |
| ZimVie (ZIMV) | United States | $0.368B | 30.98 |
| SEMPERIT AG HLD (SEIGY) | Austria | $0.349B | 0.00 |
| Verano Holdings (VRNOF) | United States | $0.349B | 0.00 |
| Quanterix (QTRX) | United States | $0.311B | 0.00 |
| Sanara MedTech (SMTI) | United States | $0.309B | 0.00 |
| Aurora Cannabis (ACB) | Canada | $0.308B | 56.10 |
| Cerus (CERS) | United States | $0.305B | 0.00 |
| Viemed Healthcare (VMD) | United States | $0.300B | 28.52 |
| OraSure Technologies (OSUR) | United States | $0.298B | 19.95 |
| Biote (BTMD) | United States | $0.252B | 5.52 |
| Canopy Growth (CGC) | Canada | $0.252B | 0.00 |
| Zynex (ZYXI) | United States | $0.234B | 49.07 |
| Sanuwave Health (SNWV) | United States | $0.231B | 3.24 |
| High Tide (HITI) | Canada | $0.205B | 0.00 |
| Utah Medical Products (UTMD) | United States | $0.204B | 15.21 |
| Brainsway (BWAY) | Israel | $0.184B | 97.80 |
| TriSalus Life Sciences (TLSI) | United States | $0.168B | 0.00 |
| MacroGenics (MGNX) | United States | $0.166B | 0.00 |
| TerrAscend (TSNDF) | Canada | $0.164B | 0.00 |
| Organigram Holdings (OGI) | Canada | $0.154B | 0.00 |
| FitLife Brands (FTLF) | United States | $0.137B | 17.17 |
| Jin Medical (ZJYL) | China | $0.114B | 0.00 |
| Quipt Home Medical (QIPT) | United States | $0.114B | 0.00 |
| Fonar (FONR) | United States | $0.092B | 12.92 |
| Oramed Pharmaceuticals (ORMP) | United States | $0.087B | 0.00 |
| Veru (VERU) | United States | $0.083B | 0.00 |
| InterCure (INCR) | Israel | $0.076B | 0.00 |
| Jushi Holdings (JUSHF) | United States | $0.069B | 0.00 |
| Exagen (XGN) | United States | $0.063B | 0.00 |
| Cytosorbents (CTSO) | United States | $0.060B | 0.00 |
| Rockwell Medical (RMTI) | United States | $0.057B | 29.17 |
| Apyx Medical (APYX) | United States | $0.054B | 0.00 |
| Hongchang (HCIL) | China | $0.051B | 0.00 |
| United-Guardian (UG) | United States | $0.046B | 13.24 |
| ImmuCell (ICCC) | United States | $0.045B | 0.00 |
| Modular Medical (MODD) | United States | $0.042B | 0.00 |
| INLIF (INLF) | $0.032B | 0.00 | |
| Safety Shot (SHOT) | United States | $0.028B | 0.00 |
| Nephros (NEPH) | United States | $0.017B | 0.00 |
| Trinity Biotech (TRIB) | Ireland | $0.015B | 0.00 |
| Cellectar Biosciences (CLRB) | United States | $0.014B | 0.00 |
| Flora Growth (FLGC) | United States | $0.013B | 0.00 |
| Innovative Eyewear (LUCY) | United States | $0.010B | 0.00 |
| NeuroMetrix (NURO) | United States | $0.009B | 0.00 |
| Meihua Medical Technologies (MHUA) | China | $0.009B | 0.00 |
| Allurion Technologies (ALUR) | United States | $0.009B | 0.00 |
| Agape ATP (ATPC) | $0.006B | 0.00 | |
| IM Cannabis (IMCC) | Canada | $0.005B | 0.00 |
| GlucoTrack (GCTK) | United States | $0.004B | 0.00 |
| Senestech (SNES) | United States | $0.003B | 0.00 |
| Akanda (AKAN) | United Kingdom | $0.002B | 0.00 |
| Sharps Technology (STSS) | United States | $0.002B | 0.00 |
| InVivo Therapeutics Holdings (NVIVQ) | United States | $0.000B | 0.00 |